Logo image of ACOG

ALPHA COGNITION INC (ACOG) Stock Fundamental Analysis

NASDAQ:ACOG - Nasdaq - CA02074J5017 - Common Stock - Currency: USD

9.09  +0.35 (+4%)

Fundamental Rating

3

Overall ACOG gets a fundamental rating of 3 out of 10. We evaluated ACOG against 551 industry peers in the Biotechnology industry. While ACOG has a great health rating, there are worries on its profitability. ACOG is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ACOG has reported negative net income.
ACOG had a negative operating cash flow in the past year.
ACOG had negative earnings in each of the past 5 years.
ACOG had a negative operating cash flow in each of the past 5 years.
ACOG Yearly Net Income VS EBIT VS OCF VS FCFACOG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

Looking at the Return On Assets, with a value of -23.95%, ACOG is in the better half of the industry, outperforming 74.95% of the companies in the same industry.
The Return On Equity of ACOG (-28.52%) is better than 79.49% of its industry peers.
Industry RankSector Rank
ROA -23.95%
ROE -28.52%
ROIC N/A
ROA(3y)-333.55%
ROA(5y)-244.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ACOG Yearly ROA, ROE, ROICACOG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -10K -20K -30K

1.3 Margins

ACOG does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ACOG Yearly Profit, Operating, Gross MarginsACOG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

The number of shares outstanding for ACOG has been increased compared to 1 year ago.
Compared to 1 year ago, ACOG has an improved debt to assets ratio.
ACOG Yearly Shares OutstandingACOG Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 10M 20M 30M 40M
ACOG Yearly Total Debt VS Total AssetsACOG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

ACOG has an Altman-Z score of 9.38. This indicates that ACOG is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 9.38, ACOG belongs to the top of the industry, outperforming 85.30% of the companies in the same industry.
There is no outstanding debt for ACOG. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 9.38
ROIC/WACCN/A
WACCN/A
ACOG Yearly LT Debt VS Equity VS FCFACOG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 10M 20M 30M 40M

2.3 Liquidity

A Current Ratio of 17.14 indicates that ACOG has no problem at all paying its short term obligations.
ACOG has a better Current ratio (17.14) than 91.11% of its industry peers.
ACOG has a Quick Ratio of 16.83. This indicates that ACOG is financially healthy and has no problem in meeting its short term obligations.
ACOG has a Quick ratio of 16.83. This is amongst the best in the industry. ACOG outperforms 90.56% of its industry peers.
Industry RankSector Rank
Current Ratio 17.14
Quick Ratio 16.83
ACOG Yearly Current Assets VS Current LiabilitesACOG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 42.65% over the past year.
EPS 1Y (TTM)42.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.12%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ACOG is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -287.30% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-1668.75%
EPS Next 2Y-287.3%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ACOG Yearly Revenue VS EstimatesACOG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2025 2026 10M 20M 30M
ACOG Yearly EPS VS EstimatesACOG Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2024 2025 2026 -2 -4 -6 -8 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ACOG reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ACOG. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ACOG Price Earnings VS Forward Price EarningsACOG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ACOG Per share dataACOG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

A cheap valuation may be justified as ACOG's earnings are expected to decrease with -287.30% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-287.3%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

ACOG does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALPHA COGNITION INC

NASDAQ:ACOG (8/5/2025, 8:00:00 PM)

9.09

+0.35 (+4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-14 2025-05-14/amc
Earnings (Next)08-20 2025-08-20
Inst Owners41.77%
Inst Owner ChangeN/A
Ins Owners8.12%
Ins Owner Change0%
Market Cap145.62M
Analysts82.86
Price Target20.4 (124.42%)
Short Float %0.73%
Short Ratio0.91
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)36.93%
Min EPS beat(2)-4.17%
Max EPS beat(2)78.03%
EPS beat(4)3
Avg EPS beat(4)62.09%
Min EPS beat(4)-4.17%
Max EPS beat(4)99.02%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)45.24%
EPS NY rev (1m)0%
EPS NY rev (3m)51.71%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)73.58%
Revenue NY rev (1m)41.19%
Revenue NY rev (3m)37.67%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 49.72
P/FCF N/A
P/OCF N/A
P/B 3.57
P/tB 3.6
EV/EBITDA N/A
EPS(TTM)-0.9
EYN/A
EPS(NY)-1.22
Fwd EYN/A
FCF(TTM)-0.46
FCFYN/A
OCF(TTM)-0.46
OCFYN/A
SpS0.18
BVpS2.55
TBVpS2.52
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -23.95%
ROE -28.52%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-333.55%
ROA(5y)-244.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 17.14
Quick Ratio 16.83
Altman-Z 9.38
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)12.76%
Cap/Depr(5y)24.09%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)42.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.12%
EPS Next Y-1668.75%
EPS Next 2Y-287.3%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y9.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year124.69%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y11.56%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.86%
OCF growth 3YN/A
OCF growth 5YN/A